21 May 2009
Low incidence of hepatic artery thrombosis after hepatic artery reconstruction in liver transplanation
O Kornasiewicz, Z Lewandowski, M Grąt, A Ścibisz, M KrawczykAnn Transplant 2009; 14(1): 43-43 :: ID: 880356
Abstract
Background: Hepatic artery thrombosis (HAT) remains an important cause
of graft loss after liver transplantation. HAT can be caused by technical, hemodynamic, or immunological factors. Bench reconstruction of anatomical variants of the hepatic artery is considered to be a major risk related to HAT. The purposes of the study were to analyse the infl uence of vascular reconstruction of the hepatic artery and its relation to HAT.
Material/Methods: We analysed, in retrospective study, 341 donors' forms
completed between January 2003 and December 2007. Vascular reconstruction was defined as an additional anastomosis between the donor's hepatic arteries which was required to obtain a full revascularisation of the graft. Any incident of HAT was confi rmed by angiography or intraoperatively during re-transplanation. The Fishers Exact Test and 95% confidence intervals (CI) estimator were applied for statistical analysis.
Results: Of 341 grafts, hepatic artery anomalies were found in 92 cases
(26.9%). In 33 (35.8%) cases hepatic artery reconstruction was required. The HAT was diagnosed in 3% (1 of 33) with hepatic reconstruction group (CI 0.1%-15.8%) compared with 1.6% of grafts (5 of 208) which did not require hepatic reconstruction (p<0.45). There was one case of hepatic thrombosis (1 of 59) totalling 1.6% in the group with hepatic anomalies without reconstruction (CI 0.04-9.1%)
Conclusions: A single hepatic reconstruction is a non significant factor for HAT. The hepatic artery anomalies do not increase the risk of HAT compared with the normal blood supply. The hepatic artery anomalies do not increase significantly the incidence of HAT compared to group of patient without anatomical abnormalities.
Keywords: Liver Transplantation
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






